{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["109(8)"],"submitter":["Ter Maaten JM"],"pubmed_abstract":["<h4>Background</h4>Loop diuretics are frequently prescribed to patients with heart failure and reduced ejection fraction (HFrEF) for the treatment of congestion; however, they might hamper uptitration of inhibitors of the renin-angiotensin system.<h4>Methods</h4>Loop diuretic dose at baseline was recorded in 2338 patients with HFrEF enrolled in BIOSTAT-CHF, an international study of HF patients on loop diuretic therapy who were eligible for uptitration of angiotensin-converting enzyme inhibitors (ACEi)/mineralocorticoid receptor antagonists (MRA). The association between loop diuretic dose and uptitration of ACEi/MRA to percentage of target dose was adjusted for a previously published model for likelihood of uptitration and a propensity score.<h4>Results</h4>Baseline median loop diuretic d"],"journal":["Clinical research in cardiology : official journal of the German Cardiac Society"],"pagination":["1048-1059"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7375987"],"repository":["biostudies-literature"],"pubmed_title":["Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction."],"pmcid":["PMC7375987"],"pubmed_authors":["Ter Maaten JM","Martens P","Zannad F","Cleland JG","Metra M","Hillege HL","Damman K","Lang CC","Samani NJ","Voors AA","Dickstein K","Anker SD","Filippatos G","Mullens W","Ng LL","Ponikowski P","van Veldhuisen DJ"],"additional_accession":[]},"is_claimable":false,"name":"Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction.","description":"<h4>Background</h4>Loop diuretics are frequently prescribed to patients with heart failure and reduced ejection fraction (HFrEF) for the treatment of congestion; however, they might hamper uptitration of inhibitors of the renin-angiotensin system.<h4>Methods</h4>Loop diuretic dose at baseline was recorded in 2338 patients with HFrEF enrolled in BIOSTAT-CHF, an international study of HF patients on loop diuretic therapy who were eligible for uptitration of angiotensin-converting enzyme inhibitors (ACEi)/mineralocorticoid receptor antagonists (MRA). The association between loop diuretic dose and uptitration of ACEi/MRA to percentage of target dose was adjusted for a previously published model for likelihood of uptitration and a propensity score.<h4>Results</h4>Baseline median loop diuretic d","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-05T12:42:34.136Z","creation":"2025-04-05T12:42:34.136Z"},"accession":"S-EPMC7375987","cross_references":{"pubmed":["32002631"],"doi":["10.1007/s00392-020-01598-w"]}}